deucravacitinib + metformin

Combination of deucravacitinib, a selective allosteric tyrosine kinase 2 (TYK2) inhibitor, and metformin, a biguanide antidiabetic agent. Deucravacitinib inhibits TYK2 to modulate cytokine signaling implicated in immune-mediated diseases such as psoriasis. Metformin lowers hepatic glucose production and improves insulin sensitivity, primarily used in type 2 diabetes. There is no evidence that this specific combination is available as a single marketed product or evaluated in clinical trials together, but each agent is independently approved (deucravacitinib for moderate-to-severe plaque psoriasis; metformin for type 2 diabetes) and commonly used as monotherapy. No clinical rationale or approved indication is established for this exact combination.